scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1111435578 |
P356 | DOI | 10.1186/S12950-018-0202-Y |
P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s12950-018-0202-y |
P932 | PMC publication ID | 6332898 |
P698 | PubMed publication ID | 30675131 |
P50 | author | Trevor T. Hansel | Q100503676 |
Carlo Alberto Volta | Q42186412 | ||
Ryan S Thwaites | Q56704841 | ||
P2093 | author name string | Gaetano Caramori | |
Riccardo Ragazzi | |||
Savino Spadaro | |||
Tommaso Mauri | |||
Paolo Ruggeri | |||
Tanushree Tunstall | |||
Mirae Park | |||
Cecilia Turrini | |||
P2860 | cites work | Acute Respiratory Distress Syndrome | Q88731683 |
IFITM3 restricts the morbidity and mortality associated with influenza | Q24369689 | ||
HMDB 3.0--The Human Metabolome Database in 2013 | Q24595162 | ||
Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults | Q26471429 | ||
A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress Syndrome | Q26765351 | ||
Metabolomics and Its Application to Acute Lung Diseases | Q26765930 | ||
Clinical utility of biomarkers of endothelial activation in sepsis--a systematic review | Q26823450 | ||
Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury | Q28566123 | ||
Acute respiratory distress syndrome: the Berlin Definition | Q29615138 | ||
Incidence and outcomes of acute lung injury | Q29615139 | ||
The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination | Q29617876 | ||
Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. | Q30381573 | ||
Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury | Q30425088 | ||
Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis | Q30572421 | ||
Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials | Q30826105 | ||
Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury | Q33512670 | ||
Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients | Q33531552 | ||
Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome | Q33750995 | ||
Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury | Q33808300 | ||
Neuromuscular blockers in early acute respiratory distress syndrome | Q34023977 | ||
Anti-TNFα therapy in inflammatory lung diseases | Q39392448 | ||
Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. | Q39499760 | ||
Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients | Q39543512 | ||
Urinary Glycosaminoglycans Predict Outcomes in Septic Shock and Acute Respiratory Distress Syndrome | Q39960097 | ||
Whole blood microRNA markers are associated with acute respiratory distress syndrome | Q40063802 | ||
Generalizable Biomarkers in Critical Care: Toward Precision Medicine | Q40210673 | ||
Endothelial Permeability and Hemostasis in Septic Shock: Results From the ProCESS Trial | Q40363013 | ||
Relationship Between Alternative Resuscitation Strategies, Host Response and Injury Biomarkers, and Outcome in Septic Shock: Analysis of the Protocol-Based Care for Early Septic Shock Study | Q40375039 | ||
Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness | Q42659568 | ||
Lower airways inflammation in patients with ARDS measured using endotracheal aspirates: a pilot study | Q42676967 | ||
SuPAR and PAI-1 in critically ill, mechanically ventilated patients | Q43480378 | ||
Urine hydrogen peroxide during adult respiratory distress syndrome in patients with and without sepsis | Q43556678 | ||
Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome | Q44663643 | ||
Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. | Q46068220 | ||
External validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome | Q46081480 | ||
Biomarkers of ARDS: what's new? | Q46126147 | ||
Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury | Q47333615 | ||
Multicohort Analysis of Whole-Blood Gene Expression Data Does Not Form a Robust Diagnostic for Acute Respiratory Distress Syndrome | Q47644676 | ||
An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. | Q47906121 | ||
Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury | Q47934955 | ||
Receptor for advanced glycation end-products is a marker of type I lung alveolar cells | Q47981118 | ||
The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients | Q47981205 | ||
KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. | Q48028199 | ||
Soluble Receptor for Advanced Glycation End-Products Predicts Impaired Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome | Q48192606 | ||
MicroRNAs as biomarkers of acute lung injury. | Q49729361 | ||
Diagnosis of acute respiratory distress syndrome by exhaled breath analysis. | Q50048226 | ||
Clinical, technological, and economic issues associated with developing new lung surfactant therapeutics. | Q52621637 | ||
Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS. | Q52633061 | ||
Recent advances in understanding acute respiratory distress syndrome. | Q52641500 | ||
Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters. | Q52656196 | ||
Stability of ARDS subphenotypes over time in two randomised controlled trials. | Q52686665 | ||
Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. | Q52691987 | ||
Cellular therapies and stem cell applications in trauma. | Q54262549 | ||
Fibrinolysis in critically ill patients | Q69223339 | ||
Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome | Q73168001 | ||
Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS | Q73251052 | ||
Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure | Q73833226 | ||
Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome | Q80867264 | ||
The acute respiratory distress syndrome | Q84693193 | ||
Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies | Q87105333 | ||
Acute respiratory distress in adults | Q34051677 | ||
Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma | Q34147463 | ||
Metabolic consequences of sepsis-induced acute lung injury revealed by plasma ¹H-nuclear magnetic resonance quantitative metabolomics and computational analysis | Q34502201 | ||
Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome | Q34515095 | ||
Comparison of two fluid-management strategies in acute lung injury | Q34528886 | ||
Rosuvastatin for sepsis-associated acute respiratory distress syndrome | Q34559446 | ||
Circulating microRNA-150 serum levels predict survival in patients with critical illness and sepsis | Q34571235 | ||
Update in acute respiratory distress syndrome | Q34711754 | ||
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial | Q34979725 | ||
Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial | Q35003693 | ||
Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury | Q35535573 | ||
Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies | Q35672843 | ||
Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature | Q35823842 | ||
Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury | Q35855126 | ||
Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis | Q35944590 | ||
Inflammasome-regulated cytokines are critical mediators of acute lung injury | Q36026253 | ||
Platelets in the pathogenesis of acute respiratory distress syndrome | Q36237204 | ||
ARDS and diffuse alveolar damage: a pathologist's perspective | Q36502837 | ||
The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) associated with critical illness | Q36616721 | ||
Impact of Initial Central Venous Pressure on Outcomes of Conservative Versus Liberal Fluid Management in Acute Respiratory Distress Syndrome | Q36689466 | ||
Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients | Q36917451 | ||
Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design | Q37213606 | ||
An integrated clinico-metabolomic model improves prediction of death in sepsis | Q37584419 | ||
Genetic heterogeneity and risk of acute respiratory distress syndrome. | Q38128254 | ||
Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. | Q38155405 | ||
Biomarkers in acute respiratory distress syndrome. | Q38168021 | ||
Biological therapies in the acute respiratory distress syndrome | Q38202165 | ||
Applying metabolomics to uncover novel biology in ARDS. | Q38204194 | ||
Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries | Q38395601 | ||
Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. | Q38431642 | ||
Characteristics of microRNAs and their potential relevance for the diagnosis and therapy of the acute respiratory distress syndrome: from bench to bedside | Q38674607 | ||
Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome | Q38700713 | ||
Fifty Years of Research in ARDS. Is Acute Respiratory Distress Syndrome a Preventable Disease? | Q38775825 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | acute respiratory distress syndrome | Q344873 |
biomarker | Q864574 | ||
P304 | page(s) | 1 | |
P577 | publication date | 2019-01-15 | |
P1433 | published in | Journal of Inflammation | Q15757699 |
P1476 | title | Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine | |
P478 | volume | 16 |
Q89585653 | A personalized approach to the acute respiratory distress syndrome: recent advances and future challenges |
Q99407989 | Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA |
Q91742889 | Causality assessment of adverse events following immunization: the problem of multifactorial pathology |
Q92017341 | Development of a biomarker mortality risk model in acute respiratory distress syndrome |
Q90320152 | Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers |
Q90217783 | Discovering Causal Mechanistic Pathways in Sepsis-associated Acute Respiratory Distress Syndrome |
Q64107664 | Heterogeneity of regional inflection points from pressure-volume curves assessed by electrical impedance tomography |
Q89530759 | R-spondin 2 mediates neutrophil egress into the alveolar space through increased lung permeability |
Q104569248 | Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury |
Q96772639 | The Acute Respiratory Distress Syndrome Biomarker Pipeline: Crippling Gaps between Discovery and Clinical Utility |
Q94953191 | The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel? |
Search more.